Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599093 | 1.00 | NFKB1 (0.34) | NFKB1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL4599052 | 1.00 | NFKB1 (0.34) | NFKB1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL9700814 | 0.82 | KDM4E (0.34) | NFKB1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL3990273 | 0.79 | — | — | |
| SCHEMBL4039881 | 0.79 | — | — | |
| SCHEMBL3990272 | 0.79 | — | — | |
| SCHEMBL514472 | 0.77 | — | — | |
| SCHEMBL514471 | 0.77 | — | — | |
| SCHEMBL1006670 | 0.76 | ALDH1A1 (0.50) | NFKB1KDM4EMAPTTHRBALOX15 | |
| SCHEMBL1006669 | 0.76 | ALDH1A1 (0.50) | NFKB1KDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116926141-A | Method for synthesizing acetylated amino acid and oligopeptide by catalyzing food-grade enzyme preparation | 华南理工大学 | 2023-10-24 | — | — | CN | disclosed |
| EP-3034512-B1 | A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions | TSETI IOULIA (GR) | 2017-12-06 | — | — | EP | disclosed |
| EP-3034512-A1 | A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions | Tseti, Ioulia (GR) | 2016-06-22 | — | — | EP | disclosed |
| US-20080051327-A1 | Crystals of an Aurora-A Tpx2 Complex, Tpx2 Binding Site of Aurora-A, Aurora-A Ligands and Their Use | EMBL (DE) | 2008-02-28 | — | — | US | disclosed |
| EP-1670909-A2 | CRYSTALS OF AN AURORA-A TPX2 COMPLEX, TPX2 BINDING SITE OF AURORA-A, AURORA-A LIGANDS AND THEIR USE | EMBL (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005040368-A2 | CRYSTALS OF AN AURORA-A TPX2 COMPLEX, TPX2 BINDING SITE OF AURORA-A, AURORA-A LIGANDS AND THEIR USE | EMBL (DE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2003057670-A2 | INDOLES AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| EP-1066297-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| EP-0973731-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-26 | — | — | EP | disclosed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999050272-A1 | PHOSPHINIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1998045256-A1 | HYDROXAMIC ACID DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |
| US-4175084-A | AND AN N-ACYL ASPARTIC ACID CARRIER, FOR PSYCHOLOGICAL DISORDERS, LEARNING ENHANCEMENT AND SLEEP INDUCTION | SENTRALINSTITUTT FOR INDUSTRIELL FORSKNING (NO) | 1979-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051327-A1 | Crystals of an Aurora-A Tpx2 Complex, Tpx2 Binding Site of Aurora-A, Aurora-A Ligands and Their Use | AURKA, AURKC, AURKB | NFKB1 3772/4885KDM4E 2207/4885MAPT 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.